UK-CAB 37; Treatment as prevention
Friday 4 February 2011
| 09:30–10:00 | Registration, refreshments and expenses |
| 10:00–10:05 | Welcome and UKCAB updates |
| 10:05–10.30 | Pre-Meeting for Gilead |
| 10:30–11:30 | iPrEX Trial design; statistical aspect of the results relating to the adherence data – Dr Colette Smith |
| 11:30–11:40 | Break |
| 11:40–12:40 | Science behind PrEP/Pharmacology Training; complexity of how drugs are absorbed and measured in different body compartments, and particularly for PrEP – Dr Steve Taylor, Heart of England NHS Trust, Birmingham |
| 12:40–14:00 | Lunch |
| 14:00–15:30 | Company meeting: Gilead |
| 15.30–15.35 | Break |
| 15:35–16:00 | UKCAB AOB |
| 16.00 | Close |
What happens to drugs in the body? (Fact sheet on pharmacokinetics)
http://i-base.info/ttfa/learning-resources/what-happens-when-you-take-a-drug
About iPrEX
http://www.niaid.nih.gov/news/QA/Pages/iPrExQA.aspx
Treatment as prevention:
http://www.avert.org/hiv-treatment-as-prevention.htm
Many HIV Positive Women on Antiretroviral Therapy Have Detectable Virus in Genital Tract
http://www.hivandhepatitis.com/recent/2010/1210_2010_b.html
Studies Look at Antiretroviral Drug Levels in Genital Fluids, Prospects for Use in Microbicides
http://www.hivandhepatitis.com/2010_conference/croi/docs/0330_2010_a.html
AVAC’s resource page on PrEP, which will direct your attention to all sorts of reports and comment on the iPrEx trial and its implicaitons:
http://www.avac.org/ht/d/sp/i/3619/pid/3619
EATG’s report on an AVAC/EATG/NAM/EUROPRISE community advocates’ meeting in Brussels last September where the implications of PrEP were gone into in some detail
http://www.eatg.org/eatg/content/download/18873/146225/file/Meeting%20PrEP%20ECAB%20Final.pdf
Presentations from EATG meeting
Aidsmap’s original news reports on iPrEx are at
http://www.aidsmap.com/Anti-HIV-drugs-prevent-HIV-infection-trial-shows-if-you-take-them/page/1553857/
and
http://www.aidsmap.com/page/1555342/
Useful articles on the problem of measuring and supporting adherence in prevention trials
http://aidsmap.com/news/Adherence-to-ARV-prevention-methods-is-challenging-partly-because-they-don-t-treat-illness/page/1438915/
and
http://aidsmap.com/Microbicides-2008-Will-adherence-issues-affect-all-the-first-generation-trials/page/1429752/ (from a few years ago, but still relevant).
Presentations from this meeting
iPrEX Trial Design; statistical aspect of the results relating to the adherence data [PDF, 120Kb]
– Dr Colette Smith, Royal Free Hospital
Genital Tract ART Implications for transmission 2010 [PowerPoint presentation, 6MB]
– Dr Steve Taylor, Heart of England NHS Trust
Financial support
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.
The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.